Strata Critical Medical, Inc. (SRTA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25M 50M 75M Q3 '21: 20.3M Q4 '21: 24.6M Q1 '22: 26.6M Q2 '22: 35.6M Q3 '22: 45.7M Q4 '22: 38.1M Q1 '23: 45.3M Q2 '23: 61M Q3 '23: 71.4M Q4 '23: 47.5M Q1 '24: 51.5M Q2 '24: 67.9M Q3 '24: 36.1M Q4 '24: 36.4M Q1 '25: 35.9M Q2 '25: 45.1M Q3 '25: 49.3M Q4 '25: 66.8M Q1 '26: 67.4M Q2 '26: 72.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 6M 12M 18M Q1 '22: 2.9M Q2 '22: 5.1M Q3 '22: 9.3M Q1 '23: 7.2M Q2 '23: 10.4M Q3 '23: 15.6M Q1 '25: 7.1M Q2 '25: 9M Q1 '26: 14.1M Q2 '26: 15.2M Q2 '22 Q1 '23 Q3 '23 Q2 '25 Q2 '26

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -9.7M Q4 '21: -10.5M Q1 '22: -13.7M Q2 '22: -9.7M Q3 '22: -10.4M Q4 '22: -19.7M Q1 '23: -12.8M Q2 '23: -12.2M Q3 '23: -7.4M Q4 '23: -35.6M Q1 '24: -9.9M Q2 '24: -12.1M Q3 '24: -7.1M Q4 '24: -5.9M Q1 '25: -5.7M Q2 '25: -4.6M Q3 '25: -5.6M Q4 '25: -6.4M Q1 '26: -3M Q2 '26: -5.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-40M -20M 0 20M 40M 60M Q3 '21: -9.2M Q4 '21: 772K Q1 '22: -11M Q2 '22: 8.4M Q3 '22: -9.2M Q4 '22: -27.3M Q1 '23: -10.2M Q2 '23: -12.2M Q3 '23: 289K Q4 '23: -33.9M Q1 '24: -4.2M Q2 '24: -11.3M Q3 '24: -2M Q4 '24: -9.8M Q1 '25: -3.5M Q2 '25: -3.7M Q3 '25: 57.4M Q4 '25: -8.8M Q1 '26: 2.2M Q2 '26: -10.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 20M 40M 60M Q3 '21: 15.9M Q4 '21: 20.6M Q1 '22: 23.7M Q2 '22: 30.5M Q3 '22: 36.5M Q4 '22: 33.2M Q1 '23: 38.1M Q2 '23: 50.6M Q3 '23: 55.9M Q4 '23: 38.5M Q1 '24: 41.4M Q2 '24: 51.6M Q3 '24: 28.6M Q4 '24: 31.4M Q1 '25: 28.9M Q2 '25: 36.1M Q3 '25: 37.7M Q4 '25: 55.1M Q1 '26: 53.3M Q2 '26: 57.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -5.8M Q4 '21: -6M Q1 '22: -10.1M Q2 '22: -11.6M Q3 '22: -6.4M Q4 '22: -9.1M Q1 '23: -16.9M Q2 '23: -8.2M Q3 '23: 2M Q4 '23: -9.3M Q1 '24: -15.6M Q2 '24: 8.4M Q3 '24: 6.4M Q4 '24: -1.8M Q1 '25: -246K Q2 '25: -3.1M Q3 '25: -37.3M Q4 '25: -8.3M Q1 '26: 3.9M Q2 '26: 5.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -5.9M Q4 '21: -6.2M Q1 '22: -10.5M Q2 '22: -11.8M Q3 '22: -6.4M Q4 '22: -9.1M Q1 '23: -17.5M Q2 '23: -8.9M Q3 '23: 1.3M Q4 '23: -9.3M Q1 '24: -16.4M Q2 '24: -7.7M Q3 '24: -3M Q4 '24: -6.3M Q1 '25: -2.9M Q2 '25: -5.3M Q3 '25: -40.2M Q4 '25: -10.2M Q1 '26: -1.3M Q2 '26: 3.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q4 '20: 25.3M Q1 '21: 26.1M Q2 '21: 51.6M Q3 '21: 69M Q4 '21: 77.7M Q1 '22: 70.8M Q2 '22: 78.5M Q3 '22: 71.5M Q1 '23: 72M Q2 '23: 73.2M Q3 '23: 81M Q1 '24: 75.8M Q2 '24: 77.6M Q3 '24: 78M Q1 '25: 79.9M Q2 '25: 81.3M Q3 '25: 82.5M Q1 '26: 90.2M Q2 '26: 86.2M Q4 '20 Q3 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.90 -0.60 -0.30 0.00 0.30 0.60 0.90 Q3 '21: -0.85 Q4 '21: -0.75 Q1 '22: -0.75 Q2 '22: -0.18 Q3 '22: -0.18 Q4 '22: -0.40 Q1 '23: -0.38 Q2 '23: -0.65 Q3 '23: -0.52 Q4 '23: -0.77 Q1 '24: -0.69 Q2 '24: -0.67 Q3 '24: -0.70 Q4 '24: -0.36 Q1 '25: -0.34 Q2 '25: -0.24 Q3 '25: 0.49 Q4 '25: 0.50 Q1 '26: 0.57 Q2 '26: 0.50 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.